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The transcription factor p63 is essential for the formation of the epidermis and other stratifying epithelia. This is
clearly demonstrated by the severe abnormality of p63-deficient mice and by the development of certain types
of ectodermal dysplasias in humans as a result of p63 mutations. Investigation of the in vivo functions of p63 is
complicated by the occurrence of 10 different splicing isoforms and by its interaction with the other family
members, p53 and p73. In vitro and in vivo models have been used to unravel the functions of p63 and its
different isoforms, but the results or their interpretation are often contradictory. This review focuses on what
mammalian in vivo models and patient studies have taught us in the last 10 years.
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INTRODUCTION
The skin protects the body against
water loss and external physical, che-
mical, and biological insults, such as
wounds, UVB radiation, and micro-
organisms (Proksch et al., 2008). The
skin barrier is formed mainly by the
epidermis, which is continuously re-
newed. Symmetric divisions of the stem
cells in the basal layer and in the
hair follicle (at least in mice) provide
new keratinocytes (Blanpain and
Fuchs, 2009). Some keratinocytes di-
vide asymmetrically, withdraw from
the cell cycle, and detach from the
basement membrane to start terminal
differentiation. Keratinocytes undergo
several discrete transcriptional stages
as they form the spinous and granular
layers and terminally differentiated,
cornified cells. Deregulation of this
tightly controlled process can lead to
pathological conditions, such as dis-
ruption of the barrier, blistering dis-
eases, inflammation, and cancer.
The human p63 gene is located
on chromosome 3q28 and compri-
ses 16 exons. Like the other p53
family members, p63 is expressed from
two different promoters, P1 and P2,
which generate two classes of pro-
teins (Figure 1). The TAp63 form
contains an N-terminal transactivation
(TA) domain, whereas the N-terminal
truncated (DNp63) isoform lacks this
domain (reviewed in Bourdon, 2007;
Candi et al., 2007a). Both TAp63 and
DNp63 can be alternatively spliced
at the 30 terminus to produce a-, b-,
g-, and d-isoforms (Mangiulli et al.,
2009). The e-isoform results from pre-
mature transcriptional termination in
exon 10 (Mangiulli et al., 2009). All 10
p63 isoforms contain a DNA-binding
domain and an oligomerization domain.
In contrast to the other isoforms,
the a-isoforms contain a sterile alpha
motif (SAM, a protein–protein interac-
tion domain), and a trans inhibitory
domain. The trans inhibitory domain
blocks transactivation by masking a few
residues on the N-terminal TA. Transla-
tion of the d-isoform generates a protein
termination in the middle of the second
transactivation domain (TA2) domain,
whereas the e-isoform terminates after
the oligomerization domain. In addition,
short isoforms lacking exon 4 have been
identified, but only in invasive breast
carcinomas (de Biase et al., 2010).
Because DNp63 isoforms lack the
N-terminal TA domain, it was origin-
ally believed that they are dominant-
negative transcriptional repressors.
However, it has become clear that they
also have transcriptional activity be-
cause they have other transactivation
domains, one located between the
oligomerization domain and the SAM
domain (Ghioni et al., 2002; Helton
et al., 2006), and another at the first 26
amino acids that are specific to the
DNp63 isoforms (Dohn et al., 2001;
Duijf et al., 2002). Despite intensive
studies, it has not been possible to
attribute specific functions to these
isoforms.
Both TAp63 and DNp63 RNA tran-
scripts are present in mouse embryos
and in postdevelopmental epithelial
cells and tissues (Mikkola, 2007; Koster
et al., 2007b), but DNp63 is more
abundant than TAp63 at the protein
level. DNp63a is expressed mainly in
the basal layer, while its expression is
downregulated in suprabasal keratino-
cytes. TAp63 is strongly expressed in
oocytes, but it is not clear whether it is
expressed at all in epithelia (Suh et al.,
2006; Livera et al., 2008).
PERSPECTIVE
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The crucial role of the transcription
factor p63 in the formation of the
epidermis and other stratifying epithe-
lia is demonstrated by two lines of
evidence. First, p63-deficient mice
have no epidermis and aberrant squa-
mous epithelia (e.g., cervix and urothe-
lium) and are also devoid of epithelial
appendages, such as mammary, sali-
vary and lachrymal glands, hair folli-
cles, and teeth (Koster et al., 2007b;
Crum and McKeon, 2010). The p63-
deficient mice also have truncated
limbs and abnormal craniofacial devel-
opment. Second, heterozygous muta-
tions in the human p63 gene are
responsible for several ectodermal dys-
plasia (ED) syndromes, which are con-
genital disorders characterized by
abnormalities of two or more ectoder-
mal structures, such as hair, teeth,
nails, sweat glands, craniofacial struc-
tures, and digits (reviewed in Rinne
et al., 2007). New direct and indirect
p63 target genes are being rapidly
identified, and the challenge is to
determine their contribution to devel-
opmental processes. On the basis of
these data sets, it was recently sug-
gested that DNp63a is involved in
regulation of development, morpho-
genesis, proliferation, tissue regenera-
tion, cell adhesion, death, and
signaling pathways (Dohn et al.,
2001; Keyes et al., 2005; Testoni
et al., 2006; Vigano et al., 2006; Yang
et al., 2006; Birkaya et al., 2007; Perez
and Pietenpol, 2007; Kouwenhoven
et al., 2010). Several of the identified
p63 target genes could be related to the
ectodermal defects observed in pa-
tients. In addition, a recent extensive
analysis of genome-wide p63 target
genes supports the idea that p63 con-
trols a network of different transcription
factors contributing to its essential role
in epithelial and limb development
(Pozzi et al., 2009). This review focuses
on the many in vivo data from studies
on mice and man during the last 10
years.
ROLE OF p63 ISOFORMS IN
EPIDERMAL DEVELOPMENT
Since the generation of two indepen-
dent p63-deficient mouse models, the
role of p63 in epidermal development
has been controversial. Although the
two p63/ strains were generated on
different genetic backgrounds using
different targeting strategies, both of
them lack epidermal appendages, have
severe defects in limbs and craniofacial
and epidermal development, and die
soon after birth. However, subtle differ-
ences between them led to strikingly
different hypotheses about the role
of p63 in the epidermis (Table 1). In
contrast to the mice developed in the
Bradley laboratory (Mills et al., 1999),
the mice generated in the McKeon
laboratory display patches of differen-
tiated keratinocytes that express kerati-
nocyte terminal differentiation markers,
such as involucrin, loricrin, and filag-
grin (Mills et al., 1999; Yang et al.,
1999). These patches were interpreted
as remnants of an initially developing
epidermis that could not be maintained
during embryogenesis. This led to the
conclusion that p63 is required for
epidermal stem cell maintenance (Yang
et al., 1999). Moreover, the surface
ectoderm covering the developing em-
bryo remains single layered and fails to
commit to an epidermal lineage (Mills
et al., 1999). Hence, these cells express
K8 and K18, but not markers of
epidermal development and differen-
tiation. Consequently, the authors con-
cluded that p63 is required for
epidermal commitment and stratifica-
tion. This view is in agreement with the
observation that p63 knockdown in
embryonic stem cells prevents ectoder-
mal cells from differentiating into K5/
K14-positive epithelial cells, whereas
DNp63 overexpression enhances the
differentiation of ectodermal cells into
keratinocytes (Medawar et al., 2008).
Interestingly, other epithelial cell fates
were not affected and K5/K18-positive
epithelial cells were present. Wolff
et al. (2009) reanalyzed the Bradley
p63/mice and made the contrasting
observation that the early stages of
epidermal and hair follicle morphogen-
esis do occur because of the expression
of C-terminally truncated p63 proteins
from the p63/ allele. Such truncated
proteins, one of which is identical to
the e-isoform (Mangiulli et al., 2009),
may induce the appearance of patches
of normal epidermis in these mutants.
The alternative explanation is that
the partial duplication of the p63
gene in the targeted allele in this
mutant promotes sporadic homologous
recombination, leading to recreation of
the wild-type p63 allele eventually
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Figure 1. The human p63 splicing isoforms. (a) Schematic representation of the exon–intron organization of the human p63 gene and the alternative
splicing events. Alternative promoter use (P1 and P2) gives rise to TA (transactivation) and N-terminally truncated (DN) isoforms. Exon numbering is
indicated. The exon color code refers to functional protein domains (see b); no fill, non-coding region. (b) Schematic representation of the human p63
protein splicing variants. For TA isoforms, only TAp63a is shown. However, TA1-containing isoforms also occur as TAp63b, g, d, and e splice variants.
aa, amino acid; DBD, DNA-binding domain; OD, oligomerization domain; SAM, sterile alpha motif; TA*, transactivation domain of the DN isoforms;
TI, transactivation inhibitory domain.
www.jidonline.org 1197
H Vanbokhoven et al.
p63, a Story of Mice and Men
Table 1. Summary of the phenotypes of the different p63 KO and transgenic mouse models
Mouse model Method Phenotype Reference
p63/
(McKeon)
Deletion of exons 6–8
(coding for the DBD),
no protein detected.
Mice backcrossed
four times to C57BL/6
K Major defects in limb, craniofacial, and epithelial
development.
K Skin contains clumps of differentiated keratinocytes
that express keratinocyte terminal differentiation
markers, such as involucrin, loricrin, and filaggrin.
K Absence of all squamous epithelia and their derivatives,
including mammary, lacrymal, and salivary glands.
K Thymus is severely abnormal in size and cellularity.
K Anomalies of the skin and skeleton are partially
ameliorated when knockout mice are crossed to mice
lacking either Ink4a or Arf tumor suppressor genes.
Rescue of epithelialization is accompanied by
restoration of keratinocyte proliferative capacity and
by expression of markers of squamous differentiation.
K The p63+/ mice display high tumor burden and
metastasis.
Yang et al. (1999)
Candi et al. (2007b)
Su et al. (2009a)
Flores et al. (2005)
p63/ Brdm2
(Bradley)
Insertional mutagenesis
resulting in a duplication
of exons 5–10, full KO,
no protein detected
K Limbs are absent or truncated.
K Skin lacks stratification and does not express
differentiation markers.
K Hair follicles, teeth, and mammary glands are absent.
K The stratified squamous epithelium in cervix and vagina
is transformed into a simple columnar epithelium.
K Ventral epithelium of the bladder not committed
to stratification nor differentiated.
K Owing to the KO method, these mice are prone
to sporadic reversion events in which the wild-type
p63 allele is recreated by spontaneous homologous
recombination, resulting in patchy normal epidermal
differentiation.
K The p63+/ mice are not prone to spontaneous
and chemically induced tumors, and mice
heterozygous for both p63 and p53 have fewer
tumors than p53+/ mice.
Mills et al. (1999)
Kurita et al. (2005)
Cheng et al. (2006)
(Mikkola et al., 2010;
Wolff et al., 2009)
Keyes et al. (2006)
p63/ Brdm3
(Bradley)
Conditional (Cre/loxP-mediated
excision of exons 5–7, DBD)
K Phenotype identical to Brdm2 mice. Mills et al. (2002)
Full TAp63
knockout mice
Non-conditional inactivation
of TAp63 isoforms (deletion of
the TA-specific exons 2 and 3)
K Expression of DNp63 isoforms not affected.
K These mice show normal epithelial morphogenesis
and are viable (data not shown or published).
K The oocytes of the TAp63/ mice, but not those
of the p53/ mice, were resistant to g-radiation.
Suh et al. (2006)
Conditional TAp63
knockout mice
Cre/lox-based inactivation
of TAp63 isoforms (deletion
of the TA-specific exon 2)
K Expression of DNp63 isoforms not affected.
K Germ-line deletion of TAp63 results in blisters,
decreased hair morphogenesis, ulcerated wounds,
decreased wound healing, and accelerated aging,
probably due to loss of TAp63 in a dermal precursor
population that resides in a hair follicle niche.
K Normal limb development.
K Development of multiple cysts in kidney, stomach,
esophagus, and bladder.
K Decreased life span.
K Epidermis-specific ablation of TAp63 does not lead
to any overt skin abnormality.
Su et al. (2009b)
Conditional TAp63
knockout mice
Cre/lox-based inactivation
of TAp63 isoforms
K Embryos do not display any overt abnormality.
K Adult phenotype not described.
Guo et al. (2009)
Inducible DNp63
knockdown mice
K14 promoter-driven
progesterone antagonist
(RU486)-inducible transgene
expression of an inverted
repeat corresponding to
exon 3 (the only exon unique
to DNp63). The resulting
dsRNA transcript is processed
into DNp63-specific siRNAs
K Suprabasal keratinocytes fail to withdraw from the
cell cycle.
K Suprabasal keratinocytes fail to initiate expression
of markers of terminal differentiation, including
K1, loricrin, and filaggrin.
K Impaired ability to heal full-thickness skin wounds.
K Basement membrane abnormalities resulting in severe
skin fragility characterized by multiple skin erosions.
Koster et al. (2007a)
Koster et al. (2009)
Table 1 continued on the following page
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Table 1. Continued
Mouse model Method Phenotype Reference
p63EEC/EEC
knock-in mice
(A Mills,
unpublished)
The EEC mutation R279H
was knocked-in by
homologous recombination
K p63EEC/EEC mice have truncated forelimbs, no hind
legs, ectodermal dysplasia, and craniofacial anomalies
(similar to those of p63–/– mice).
K p63+/EEC mice have normal limbs, mild ectrodactyly
is rarely observed (rest of phenotype unpublished).
(Lo Iacono et al., 2008;
Moretti et al., 2010)
DNp63a
transgenic mice
K5-driven transgene
expression
K No abnormalities reported upon overexpression
in wild-type mice.
K Complementation of p63/ mice (McKeon lab)
results in formation of a substantial epidermal basal
layer, with expression of genes characteristic of the
basal layer. No significant increase in K1 and filaggrin.
K The p63/ thymic morphology and cellularity are
partially restored by complementation by DNp63a
but not by TAp63a.
Candi et al. (2006a)
Candi et al. (2007b)
TAp63a
transgenic mice
K5-driven transgene
expression
K No abnormalities reported upon overexpression
in wild-type mice.
K Like p63/ mice, no signs of epithelialization
upon overexpression in p63/ mice (McKeon lab).
K Complementation of p63/ with both TA
and DNp63a results in greater (but still partial)
reepithelialization characterized by several layers
of keratinocytes that express both basal and
suprabasal markers (K14, K1, and filaggrin).
Candi et al. (2006a)
DNp63a
transgenic mice
Progesterone antagonist
(RU486)-inducible
transgene expression
K Ectopic DNp63a expression in lung epithelium
does not induce squamous metaplastic lesions.
Koster et al. (2004)
TAp63a
transgenic mice
Progesterone antagonist
(RU486)-inducible
transgene expression
K Ectopic TAp63a expression, but not DNp63a,
in lung epithelium induces squamous metaplastic
lesions and K5 and K14 expression.
K Epidermal TAp63a overexpression in wild-type mice
results in severe hyperplasia (due to hyperproliferation)
and perturbed epidermal differentiation, indicating an
apparent failure of the basal keratinocytes to commit
to terminal differentiation.
K Epidermal TAp63a overexpression in conditions with
reduced DNp63 expression (=p63+/ mice) results
in mice that appear dehydrated, and their skin
cracks and peels due to strong inhibition of terminal
differentiation.
K Epidermal TAp63a expression accelerates chemically
induced tumor development and progression,
frequently resulting in epithelial–mesenchymal
transitions to spindle cell carcinomas and lung
metastases.
Koster et al. (2004)
Koster et al. (2006)
DNp63a
transgenic mice
Tissue-specific tetracycline-
inducible expression using
mice expressing the rtTA
from a tissue-specific promoter
(SPC) for lung epithelium;
K5 promoter for epidermal
expression)
K Overexpression of DNp63a in lung epithelium results
in squamous metaplasia, with de novo induction
of K5 and K14, as well as transdifferentiation to
the epidermal cell lineage.
K Complementation of Brdm2 p63/ mice partially
restores the skin phenotype and gives rise to isolated,
small pockets of stratified epithelium resembling fully
differentiated skin, with expression of K5, K14, K1, K10,
and filaggrin.
K Overexpression in wild-type epidermis results in
severe defects in hair follicle development and cycling,
eventually leading to severe hair loss and a depleted
hair follicle stem-cell niche. In addition, the cell
fate of hair follicle keratinocytes is switched to
an interfollicular epidermal cell identity.
Romano et al. (2009)
Romano et al. (2010)
DNp63b
transgenic mice
Tissue-specific tetracycline-
inducible expression using
mice expressing the rtTA
from a tissue-specific promoter
K Phenotype identical to DNp63a transgenic mice
when overexpressed in lung and p63/ epidermis.
Romano et al. (2009)
Abbreviations: DBD, DNA-binding domain; dsRNA, double-stranded RNA; EEC, ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome; KO,
knockout; DN, N-terminally truncated; rtTA, reverse tetracycline-activator; siRNA, small interfering RNA; SPC, surfactant protein-C; TA, transactivation.
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resulting in the occurrence of normal
skin patches (Mikkola et al., 2010).
The finding that inactivation of p63 in
mice is accompanied by aberrantly
increased expression of the Ink4a and
Arf tumor suppressors (Su et al., 2009a)
supports the idea that p63 is needed to
control senescence and apoptosis in-
duction, allowing proper epidermal
homeostasis. Indeed, p63/ skin and
skeleton phenotypes are partially ame-
liorated in mice lacking either Ink4a or
Arf, suggesting that abnormal upregula-
tion of Ink4a and Arf is incompatible
with skin development. Both p63/;
Ink4a/ epidermis, and p63/;
Arf/ epidermis clearly stratified and
expressed late epidermal differentiation
markers such as filaggrin.
To address the in vivo role of speci-
fic p63 isoforms, several genetic mouse
models were developed (Table 1).
Downregulation of the DNp63 isoforms
in keratinocytes of mice at birth or 3
weeks later caused severe skin erosions
characterized by suprabasal epidermal
proliferation, delayed terminal differ-
entiation, and basement membrane
abnormalities (Koster et al., 2007a,
2009). Through interference with struc-
tural stability of the epidermis, these
defects likely contributed to the ob-
served skin fragility. These data under-
score the importance of DNp63 isoform
expression in keratinocytes to maintain
epidermal integrity by inducing the
expression of several target genes
(Vigano et al., 2006; Koster et al.,
2007a, 2009). TAp63/ mice carry-
ing a deletion of the TA-specific exons
2 and 3 (Suh et al, 2006) and epider-
mal-specific TAp63/ mice did not
display any of these skin abnormalities
(Su et al., 2009b), confirming that the
TAp63 isoforms have no significant role
(if at all) in epidermal differentiation or
stratification. In contrast, another full
TAp63/ mouse, the Flores strain
carrying a deletion of exon 2, develops
skin blisters due to reduced adherence
of the epidermal cells to the basement
membrane and skin ulcerations (Su
et al., 2009b). In addition, these mice
display decreased hair morphogenesis
and impaired wound healing, probably
due to premature senescence of dermal
and epidermal cells (Su et al., 2009b).
The reason for the differential pheno-
types of both full TAp63-deficient
strains is unknown (genetic background
differences?), but is not due to affected
DNp63 expression levels (Suh et al.,
2006; Su et al., 2009b). The phenotype
of the Flores TAp63/ strain suggests
that TAp63 expression in the dermis
contributes to epidermal homeostasis,
indicating that different p63 isoforms
can have different functions in epider-
mis and dermis.
TAp63a-complemented p63/
mice (McKeon strain) do not differ from
p63/ mice, whereas DNp63a-com-
plemented mice develop a substantial
basal layer (Candi et al., 2006a).
Double-complemented mice exhibit a
greater degree of reepithelialization
with expression of keratins of the basal
layer (K5 and K14) and differentiation-
specific markers, such as K1 and
loricrin. However, complete cornifica-
tion is impaired. These data suggest
that TAp63a acts at the same time or
after DNp63a. Another complementa-
tion study using the Bradley p63/
mice indicated that epidermal reex-
pression of either DNp63a or DNp63b
is sufficient for the generation of
properly developed and stratified epi-
dermis in several areas (Romano et al.,
2009). However, because the Bradley
p63/ mice used in this study are
prone to genetic recreation of the wild-
type allele, these data should be
considered with care. In addition, in
both the Candi and Romano papers, the
use of strategies based on the K5
promoter to complement p63/ mice
that have poor or no K5 expres-
sion hampers the interpretation of the
results.
Interestingly, overexpression of
TAp63a in lung induced the transfor-
mation of a single-layered epithelium
into a stratified keratinizing epithelium,
but this did not occur upon over-
expression of DNp63a (Koster et al.,
2004). In contrast, another study found
that transgenic overexpression of either
DNp63a or DNp63b in the lung could
induce squamous metaplasia, with de
novo induction of K5 and K14, as well
as transdifferentiation to the epidermal
cell lineage (Romano et al., 2009). This
indicates that the SAM domain is not
required for the latter effects and that
overexpression of both TA or DNp63
isoforms can instruct a stratification
program in epithelia that are normally
single layered. The reason for the
discrepancy between the two studies
is unknown, but it might be due to
differences in the timing of expression
or in expression levels obtained in the
different transgenic mouse strains.
In conclusion, more studies are
needed to understand the physiological
importance of the different p63 iso-
forms more clearly, and development
of additional isoform-specific knockout
mice would provide useful new tools
for that.
IS p63 A GUARDIAN OF EPITHELIAL
STEMNESS?
DNp63a is strongly expressed in the
basal epidermal layer, where epithelial
cells with high clonogenic and prolif-
erative capacity reside. There are many
indications that p63 is required to
maintain the proliferative potential of
the epidermis (Truong et al., 2006;
Senoo et al., 2007), but whether p63
is required for maintenance of stem
cells is debatable because p63 is also
expressed in non-stem cells (Koster
et al., 2007b). However, one cannot
exclude the possibility that p63 has
functions both in stem cells and non-
stem cells. Consistent with the fact that
the in vivo expression of p63 in the
epidermis is correlated with the locali-
zation of stem cells, Senoo et al. (2007)
found that in vitro p63 knockdown in
epidermal cells reduced their clono-
genic potential. In addition, in vitro
overexpression of microRNA-203 in
primary mouse or human keratino-
cytes, which represses p63 translation,
significantly reduces their clonogenic
capacity (Lena et al., 2008; Yi et al.,
2008). This finding was confirmed
in vivo in mice (Yi et al., 2008). When
microRNA-203 is absent or decreased
in mice, p63 expression and keratino-
cyte cell proliferation are no longer
restricted to the basal layer (Yi et al.,
2008). The results suggest that by
regulating the p63 expression level,
microRNA-203 functions as a key
molecule controlling the decision of
p63-dependent proliferation of epithe-
lial precursor cells or their exit from the
cell cycle during keratinocyte differen-
tiation.
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Because epidermis-specific TAp63/
mice do not display any overt skin
abnormalities, it can be concluded
that this p63 isoform is not essen-
tial to maintain the cell autonomous
epidermal turnover, at least in vivo
(Su et al., 2009b). Consequently,
TAp63/ epidermal cells derived
from a cross of floxed TAp63 mice
with K14Cre mice formed colonies
at the same frequency as wild-type
cells (Su et al., 2009b). Surprisingly,
TAp63/ epidermal cells derived
from full TAp63/ mice were defec-
tive in their ability to form colonies (Su
et al., 2009b). The reason for the
different effect on clonogenicity de-
pending on the TAp63 deletion strategy
is currently not known, but may be due
to the difference in timing of TAp63
deletion in the different models. In full
TAp63/mice, the absence of TAp63
results in increased proliferation and
premature senescence of dermal stem
cells that reside in the hair follicle (Su
et al., 2009b). Taken together, these
data suggest that TAp63 can regulate
the proliferative capacity of different
stem cell compartments by preventing
premature senescence or rundown of
stem cells. The finding that inactivation
of p63 in mice is accompanied by
aberrantly increased expression of the
Ink4a and Arf tumor suppressors (Su
et al., 2009a), both of which are
involved in cellular senescence and
apoptosis, supports this hypothesis.
Thymic epithelial cells lacking all
p63 isoforms do not have a prolifera-
tion defect (Senoo et al., 2007). Intrigu-
ingly, the lack of p63-triggered
apoptosis explains the reduced thymic
size and suggests that p63 acts as a
prosurvival factor for the proliferation-
competent embryonic and adult epithe-
lial stem cells. In line with this model,
FgfR2-IIIb and Jag2 were identified as
p63 target genes affecting thymic
epithelial stemness and development
(Candi et al., 2007b). Hence, the
current data indicate that p63 expres-
sion affects proliferative capacity either
by controlling proliferation or by pre-
venting cell death, depending on the
cell type or the differentiation status of
the cell. The relative contribution of the
p63 isoforms in these processes needs
further clarification.
MUTATIONS IN THE p63 GENE
ARE ASSOCIATED WITH MULTIPLE
CONGENITAL ANOMALIES
Unequivocal evidence has been pro-
vided that p63 has a major role in
embryonic development, and particu-
larly in the development of ectodermal
lineages. p63 Knockout mice have
severe developmental abnormalities,
and dominant p63 mutations in hu-
mans cause congenital ED syndrome
(Celli et al., 1999; Mills et al., 1999;
Yang et al., 1999). So far, mutations in
the human p63 gene have been re-
ported in seven clinically different
diseases. Five of them are ED syn-
dromes characterized by congenital
anomalies: ectrodactyly, ED, and cleft
lip/palate syndrome (EEC, OMIM
604292); ankyloblepharon, ectodermal
defects, and cleft lip/palate syndrome
(AEC, OMIM 106260); limb mammary
syndrome (OMIM 603543); acro-der-
mato-ungual-lacrimal-tooth syndrome
(OMIM 103285); and Rapp–Hodgkin’s
syndrome (OMIM 129400) (Celli et al.,
1999; McGrath et al., 2001; van
Bokhoven et al., 2001; Duijf et al.,
2002; Kantaputra et al., 2003). Three
main hallmarks characterize the wide
spectrum of disease phenotypes: ED,
orofacial clefting, and limb malforma-
tions (ectrodactyly/split hand/foot mal-
formation (SHFM) and syndactyly). The
other two conditions are non-syndro-
mic: isolated SHFM (SHFM4, OMIM
605289) (Ianakiev et al., 2000) and
non-syndromic cleft lip (Amiel et al.,
2001; Leoyklang et al., 2006).
Patients with a deletion in 3q27
covering the complete p63 gene do
not show any ED features (Chitayat
et al., 1996; Pollazzon et al., 2009),
and heterozygous p63 knockout mice
(p63þ /) do not display ectodermal
defects either (Mills et al., 1999; Yang
et al., 1999). These findings suggest
that the pathogenic mechanism is
dominant-negative or gain-of-function
mutation rather than haploinsuffi-
ciency. However, heterozygous p63þ /
EEC mice generated by knocking
in the R279H allele rarely display
ectrodactyly (Lo Iacono et al., 2008),
whereas p63EEC/EEC mice resemble
p63/ mice. The development of
EEC in patients carrying this mutated
allele (Rinne et al., 2007) indicates that
mouse models react somewhat differ-
ently from humans to disturbed bal-
ances of wild-type versus mutated p63
molecules. This difference in response
could be due to differences in the
stability of the mutated mouse and
human p63 proteins.
GENOTYPE–PHENOTYPE
CORRELATIONS AND CLINICAL
VARIABILITY OF p63-ASSOCIATED
SYNDROMES
Other human ED disorders besides the
seven disorders described in the pre-
vious section are quite likely caused by
mutation of the p63 gene. In addition,
reduced penetrance of phenotypic fea-
tures and wide clinical variability are
often seen within families sharing the
same p63 mutation. Therefore, it is
possible that some affected individuals
have mild or nearly undetectable ab-
normalities, which would lead to
underestimation of p63 mutation
frequency in the population (Itin,
2009). The appearance of clinically
different phenotypes originating from
mutations in the same gene can be due
to different mechanisms. First, muta-
tions affecting different protein do-
mains and functional properties of the
protein might generate different clinical
phenotypes. The spectrum of mutations
in the p63 gene is one of the best
examples of such genotype–phenotype
correlations. The different mutation
pattern is most prominent in the EEC
and AEC syndromes, which are mostly
caused by missense mutations in the
DNA-binding domain and SAM do-
main, respectively (reviewed in Rinne
et al., 2007). The signature of acro-
dermato-ungual-lacrimal-tooth syn-
drome is the gain-of-function R298Q/
G mutation in the DNA-binding do-
main; this mutation is not seen in any of
the other p63-associated conditions
(Rinne et al., 2006). For other p63-
related diseases, specific domain clus-
tering has not been clearly established
yet, but most of the corresponding
mutations are syndrome specific. How-
ever, some p63 mutations have been
linked to distinct clinical conditions. A
second mechanism underlying clinical
variability is phenotypic modulation by
genetic background and/or environ-
mental factors. Prominent examples of
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such mutations are those affecting
R280 in EEC syndrome and in SHFM4,
and mutations affecting R313 in EEC
syndrome and in non-syndromic cleft
lip. Other good examples are the over-
lapping mutations found in AEC and
Rapp–Hodgkin’s syndrome patients.
These genotypic similarities are re-
flected in the strong phenotypic over-
lap between these two conditions,
which led to the suggestion that Rap-
p–Hodgkin’s syndrome and AEC syn-
dromes are different manifestations of
the same clinical entity (Dianzani
et al., 2003; Bertola et al., 2004; Kannu
et al., 2006; Rinne et al., 2007, 2009;
Clements et al., 2010). However, more
subtle clinical variability is frequently
evident within specific syndromes.
Phenotypic analysis of more than 25
patients for each of the five EEC hot-
spot mutations revealed that all symp-
toms display variable expressivity for
each of these mutations. None of the
individual clinical features is fully
penetrant, and most have an incidence
below 50% (Rinne et al., 2007). A third
explanation for the observed clinical
variability is provided by the specific
effects of individual mutations, even for
those that occur within one particular
syndrome. For example, more than
80% of the patients carrying the R304
mutation had cleft lip/palate, whereas
only one of the patients carrying the
R227 mutation showed cleft palate
only. The different phenotypes of these
two mutations are not just a reflection
of their severity, because other features,
such as urogenital anomalies, are most
frequently seen in association with the
R227 mutation.
What are the molecular determi-
nants of this clinical variability? One
possibility is that syndrome-specific
mutations might have overlapping as
well as specific functional conse-
quences. Of the five EEC syndrome
hot-spot mutations, only R279 and
R304 are directly involved in DNA
binding (Celli et al., 1999). Mutations
of amino-acid residues that are not
directly involved in DNA binding
(R204, R227 and R280) most likely
affect the global protein structure or
stability, and thereby influence the
transcription of target genes. Indeed,
several naturally occurring p63 SAM
domain mutants (and C-terminal there-
of) were shown to be less prone to
sumoylation, resulting in stabilization
of the mutant protein and increased
transcriptional activity (reviewed in
Stehmeier and Muller, 2009). There-
fore, we hypothesize that most, if not
all, of the heterozygous p63 mutations
behave differently at specific promoters
to affect subsets of genes, and that this
contributes to the clinical variability in
EEC syndrome. To investigate this
hypothesis, it is imperative to study
the effects of individual mutations on
the expression of p63 target genes. In
addition, chromatin immunoprecipita-
tion–sequencing experiments compar-
ing the in vivo genomic DNA-binding
sites of wild-type p63 and the DNA-
binding domain mutant in primary cells
will identify which mutants have a
different DNA-binding behavior.
p63 REGULATES EPITHELIAL
ADHESION
Because the epidermis is confronted
with much mechanical stress, its struc-
ture has to be very compact and solid.
Cells are anchored together by adhe-
rens junctions and desmosomes, and
cells in the basal layer are anchored to
the underlying basal lamina by actin-
linked focal adhesions or intermediate
filament-linked hemidesmosomes. Sig-
nals are transmitted through the actin
or intermediate filaments that are an-
chored to these junctions. The gene for
P-cadherin, an adherens junction pro-
tein, can be activated by various p63
isoforms (Shimomura et al., 2008).
Interestingly, homozygous mutations
of the P-cadherin gene (CDH3) under-
lie hypotrichosis with juvenile macular
dystrophy (OMIM 601553; (Indelman
et al., 2002) and ED, ectrodactyly, and
macular dystrophy syndrome (OMIM
225280; (Kjaer et al., 2005), both of
which have strong similarity to the p63-
associated disorders. Also Perp protein,
a stabilizer of desmosomal complexes
within cell–cell junctions, can be regu-
lated and activated by various p63
isoforms (Ihrie et al., 2005). Further-
more, integrin-a3, a component of the
basal lamina laminin receptor, is a
TAp63g target (Kurata et al., 2004),
and DNp63a was shown to bind and
activate several integrin (a3, b4, a5,
and a6) promoters and the laminin-g2
promoter (Carroll et al., 2006). Finally,
dystonin (BPAG1), which anchors ker-
atin-containing filaments to hemides-
mosomes, and protein keratin-14 can
be regulated by TAp63g and DNp63a,
respectively (Osada et al., 2005; Ortt
and Sinha, 2006; Candi et al., 2006a;
Romano et al., 2007). Consequently,
knockdown of endogenous p63 in a
human epithelial breast cell line and in
keratinocytes led to detachment of cells
from the culture plate, downregulation
of cell adhesion-associated genes, and
cell death (Carroll et al., 2006), im-
plicating p63 as a key regulator of
cellular adhesion.
Several lines of evidence indicate
that p63 is both a direct and an indirect
regulator of IkB kinase-a (IKKa), which
has been linked to epidermal differen-
tiation, proliferation, and limb devel-
opment (Hu et al., 1999, 2001; Candi
et al., 2006b; Marinari et al., 2009).
Accordingly, mutant p63 proteins ex-
pressed in ED patients exhibit defects in
inducing IKKa, probably by dominant-
negative effects of mutant DNp63a on
the IKKa promoter (Koster et al., 2009).
DNp63a has been shown to bind to the
GATA-3 promoter and activate gene
transcription (Candi et al., 2006b).
GATA-3 is a transcription factor in-
volved in skin barrier formation and
hair follicle cell fate decision (Kaufman
et al., 2003; de Guzman Strong et al.,
2006; Candi et al., 2006b; Chikh et al.,
2007), but its specific function in
epidermal development and differen-
tiation has not been established yet.
Interestingly, GATA-3 together with
Ets-1 can regulate IKKa.
Finally, Fras1, which is required
for maintaining the integrity of the
epidermal–dermal interface at the
basement membrane, was identified
as a DNp63a target gene (Koster
et al., 2007a). It was proposed that
DNp63 initially induces Fras1 expres-
sion to ensure strong epidermal–dermal
attachment. This occurs before IKKa
induction, which initiates epidermal
terminal differentiation, and finally
results in the formation of the spinous
layer (Koster et al., 2007a).
All together, these data indicate that
DNp63 is the major isoform regulating
cellular adhesion in the epidermis and
1202 Journal of Investigative Dermatology (2011), Volume 131
H Vanbokhoven et al.
p63, a Story of Mice and Men
suggest that the human AEC skin
phenotype could be mimicked in
mouse skin by downregulating
DNp63a. Indeed, conditional short
hairpin RNA-mediated downregulation
of DNp63 in mouse epidermis caused
severe skin erosions, resembling lesions
that develop in AEC patients (Koster
et al., 2009).
p63 TARGET GENES IN LIMB
DEVELOPMENT
The p63 has an important role in limb
development, as mutations in p63 give
rise to complex syndromes as well as to
isolated SHFM (SHFM4) (Ianakiev
et al., 2000). However, p63 mutations
explain only about 10% of all SHFM
patients, and at least five other chro-
mosomal loci for non-syndromic SHFM
have been reported (Scherer et al.,
1994; Del Campo et al., 1999; Ianakiev
et al., 2000; de Mollerat et al., 2003;
Faiyaz-Ul-Haque et al., 2005; Ugur
and Tolun, 2008). The SHFM1 locus
on chromosome 7q21 has been subject
of various translocations, inversions,
deletions, and duplications (Scherer
et al., 1994). The smallest region of
overlapping deletions in SHFM1 pa-
tients encompasses only four genes:
SLC25A13, DSS1, DLX5, and DLX6.
Interestingly, it has been demonstrated
that p63 regulates the expression of
Dlx5 and DLX6 (Lo Iacono et al.,
2008). These genes are strongly ex-
pressed in the apical ectodermal ridge
(AER) of the developing limbs of mice
(Acampora et al., 1999; Robledo et al.,
2002) and in the fins of zebrafish
(Simeone et al., 1994). The AER is
critical for limb outgrowth and pattern-
ing (Capdevila and Izpisua Belmonte,
2001), and there is strong evidence that
failure to maintain AER signaling is the
main pathogenic mechanism in ectro-
dactyly (Duijf et al., 2003). The im-
portance of the DLX5 and DLX6 genes
in limb development has been investi-
gated in mouse models, which re-
vealed that only simultaneous ablation
of the two Dlx genes gives rise to limb
defects (Robledo et al., 2002). This is
analogous to the condition generated
by the SHFM1-associated deletions in
humans. However, an atypical SHFM1
deletion was recently identified. This
deletion overlaps previous deletions
but does not affect DLX5 and DLX6
(Kouwenhoven et al., 2010). In the
same paper, a genome-wide profile of
p63-binding sites was produced using
chromatin immunoprecipitation-se-
quencing. One cis-regulatory element
identified by DNA-binding profiling is
located in the minimal SHFM1 critical
region and acts as an enhancer element
for the expression of DLX5 and DLX6
mediated by p63 during embryonic
limb development. It was shown that
loss of this enhancer element leads to
SHFM. This result reveals a direct
molecular pathway between p63 and
DLX5 and DLX6 important for normal
development and/or maintenance of
the AER during limb development.
In addition, it was shown that brachy-
ury, a gene with an important role
in AER and limb development (Liu
et al., 2003), is a direct transcriptional
target of DNp63a and that it is not
expressed in p63/ mouse embryos
(Cho et al., 2010). This indicates that
several genes participate in p63-driven
limb development.
RECIPROCAL INTERACTION
BETWEEN p63 AND IRF6 IN
DEVELOPMENT OF THE PALATE
Orofacial clefting, one of the hall-
marks of p63-associated disorders,
can occur in various forms. EEC syn-
drome patients usually have cleft lip/
palate, limb mammary syndrome pa-
tients have cleft palate only, and AEC
syndrome patients can have cleft palate
only, cleft lip only, or cleft lip/palate.
The varied manifestations of orofacial
clefts are remarkable, because clefting
of the lip and palate are distinct
processes. Besides p63 mutations, only
IRF6 mutations are known to cause
variable combinations of cleft lip and
palate in syndromes such as Van der
Woude syndrome (OMIM 119300) and
the related popliteal pterygium syn-
drome (OMIM 119500) (Kondo et al.,
2002). Moreover, polymorphisms in
the IRF6 gene contribute to the pre-
valence of the more common multi-
factorial forms of orofacial clefting
(Zucchero et al., 2004; Scapoli et al.,
2005).
Recently, a search for evolutionarily
conserved elements in the IRF6
locus identified a single-nucleotide
polymorphism affecting an AP2a-bind-
ing site in a conserved element 10 kb
upstream of IRF6, which increases the
risk of cleft lip (Rahimov et al., 2008).
Interestingly, the same conserved ele-
ment was contained in a p63-binding
site (Kouwenhoven et al., 2010).
Indeed, it was established that this
p63-binding site is crucial for IRF6
expression during palatal development
(Thomason et al., 2010). An epistatic
interaction between p63 and IRF6 was
established by crossing the correspond-
ing heterozygous mouse mutants, in
both of which the palate develops
normally. However, transheterozygous
mice simultaneously carrying a hetero-
zygous deletion of p63 and the Irf6
knock-in mutation R84C displayed
ectodermal abnormalities that led to
cleft palate. Upregulation of IRF6 by
DNp63 in turn induced proteasome-
mediated DNp63 degradation (Moretti
et al., 2010). Together, these data
reveal an auto-regulatory feedback
loop between p63 and IRF6 in orofacial
development (Gritli-Linde, 2010).
The preceding sections show that
several p63-regulated genes are impor-
tant for various aspects of normal
ectodermal development. Thus, p63
target genes could include many other
prime candidate genes affected in EDs
that have not been resolved at the
molecular level. In addition, the coding
regions or the cis-regulatory elements
might contain polymorphisms that
contribute to the clinical variability of
p63-associated disorders. As discussed
above, such polymorphisms might also
be risk factors for non-syndromic com-
mon disease, such as orofacial clefting
(Beaty et al., 2010). The list of p63
target genes could provide insight into
the molecular and cellular processes
behind the wide variety of congenital
anomalies observed in patients carrying
a p63 mutation.
p63 IN CANCER
The p63 is clearly involved in cancer
development, but the underlying mo-
lecular mechanisms have not been
fully elucidated. This is, in part, due
to the complexity of the p63 gene,
which encodes different isoforms with
distinct functions in terms of enhancing
or blocking proliferation and inducing
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or blocking cell death. The p63 gene is
frequently deregulated or overex-
pressed in human cancers (Crum and
McKeon, 2010), indicating that it is
strongly related to cancer develop-
ment. However, the fact that p63 is
very rarely deleted or mutated in hu-
man cancers suggests that its role is
different from that of its sibling, p53.
However, p63 knockdown increases
the transforming potential of p53/
mouse embryonal fibroblasts (Lang
et al., 2004). Because the two major
p63 isoforms have profoundly distinct
biological effects, as discussed above,
several groups investigated the selec-
tive involvement of the TA or DN
isoforms in cancerogenesis. Indeed,
DNp63 isoforms are often overex-
pressed in tumors associated with poor
prognosis (Deyoung and Ellisen, 2007),
whereas TAp63 is induced in cancer
cells in response to chemotherapeutic
drugs and, in a p53-independent man-
ner, can induce cell-cycle arrest, se-
nescence, DNA repair, and apoptosis
(Gressner et al., 2005; Guo et al., 2009;
Lin et al., 2009). In agreement with
these results, TAp63 acts independently
of p53 to induce apoptosis in response
to DNA damage in female germ cells as
well (Suh et al., 2006). Upon genotoxic
stress, TAp63 is phosphorylated by the
kinase c-Abl and induces apoptosis of
oocytes, thereby protecting the female
germ line (Gonfloni et al., 2009). This
finding raised the interesting concept
that althoigh p53 monitors the genome
of somatic cells, p63 has an analogous
role in the female germ line. Beside the
relevance of this concept for oocyte
pool control, it also has interesting
implications for cancer treatment. In-
deed, although TAp63 is almost exclu-
sively expressed in oocytes, DNp63 is
highly frequent in cancer cells. There-
fore, during chemotherapy, inhibition
of c-Abl (and therefore of p63 activity)
by imatinib (commercial name Glee-
vec, Novartis, Switzerland) blocks the
lethal effect of TAp63 on oocytes as
well as the survival effect of DNp63 on
cancer cells (Gonfloni et al., 2009).
This protects the oocytes from toxicity
and thereby improves fertility after
cancer treatment, and at the same time,
it enhances the efficacy of cancer
chemotherapy. Theoretically, this
should widen the therapeutic window,
but this possibility has to be confirmed
and validated in several cancer models.
Unfortunately, the studies on mice
produced conflicting results on the
in vivo role of p63 in tumor progres-
sion (reviewed in Candi et al.,
2007a; Collavin et al., 2010; Flores,
2007). Indeed, careful analysis of the
tumor predisposition of p63þ / and
p73þ / mice backcrossed four times
to C57BL/6 mice revealed consistently
increased cancer sensitivity (Flores
et al., 2005). A high percentage of
tumors in the p63þ / and p73þ /
mice exhibited loss of the remaining
wild-type allele. Conversely, Bradley’s
mixed background p63þ / mice did
not show spontaneous or chemically
induced tumor development (Keyes
et al., 2006). These findings point to
the important contribution of genetic
modifiers to cancer predisposition.
Here, kinases (eg, c-Abl), interactors
(eg, ASPP family, PML, and PIN-1), or
single-nucleotide polymorphisms inter-
fering with p63 activity could have
crucial roles, and therefore this area of
research is currently very active.
Whereas gain of TAp63 induces senes-
cence in mouse embryonal fibroblasts,
TAp63 deficiency increases prolifera-
tion and enhances Ras-mediated onco-
genesis in vivo when p53 is deficient
(Guo et al., 2009). TAp63 induces
senescence independently of p53,
p19Arf and p16Ink4a, but it requires
p21Waf/Cip1 and Rb (Guo et al., 2009).
Hence, the studies on mice indicate
that TAp63 isoforms function as tumor
suppressors by regulating senescence
through p53-independent pathways.
The most striking aspect of p63
function in cancer was discovered very
recently: p63 is a suppressor of metas-
tasis. TAp63 prevents invasiveness and
metastasis of epithelial tumors by con-
trolling expression of a crucial set of
metastasis-inhibitor genes (Adorno
et al., 2009; Muller et al., 2009; Su
et al., 2010). The antimetastatic role of
TAp63 is disabled by the physical
incorporation of p63 into a ternary
protein complex together with mutant
p53 and transforming growth factor
b-activated Smads (Adorno et al.,
2009). Considering that p53 is mutated
in over two-thirds of all human cancers,
and that metastasis is one of the most
lethal steps in cancerogenesis, this
finding is of primary importance. Ac-
cordingly, in a set of 1,200 patients with
breast cancers, expression profiling of
two p63 targets genes, Sharp1 and
cyclin G2, was used to stratify all
patients in two classes with very distinct
prognosis (Adorno et al., 2009). Strik-
ingly, patients who carried tumors
expressing high levels of Sharp1 and
cyclin G2 had a significantly higher
probability of disease-free survival. In
addition, mutant p53 can significantly
decrease activation of proapoptotic
target genes by wild-type p53, TAp63,
and TAp73 (Schilling et al., 2010). These
data indicate that oncogenic p53 mu-
tants can genetically interact with p63
(and p73) to promote cellular resistance
to DNA damage-induced apoptosis.
Taken together, these results create
much interest in the role of p63
in cancer and indicate that p63 iso-
forms could be anticancer targets:
restoring the correct ratio of the two
isoforms could enable more efficient
cancer treatment with less toxicity.
Upregulated protein levels of TAp63
in tumor cells could counterbalance
the tumor-promoting activity of the
DNp63 isoforms.
CONCLUSION
We are just beginning to understand
the pathways and networks controlled
by p63, which explain, in part, the EDs
observed in patients carrying hetero-
zygous p63 mutations. It was originally
thought that these dysplasias were
caused by inactivating mutations in
p63 that rendered these mutants domi-
nant-negative molecules. However, the
manifestations of the disease depend
on which protein domain carries the
mutation. This indicates that the origi-
nal hypothesis is only partially true and
that particular mutant p63 proteins
activate different p63 target genes. This
notion is now supported by experimen-
tal evidence. The many different hu-
man ‘‘models’’ available make it
possible to gain a deeper understanding
of the in vivo role of the different p63
mutants.
Because the different p53/p63/p73
family members exist in multiple iso-
forms and can interact with each other,
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determining the involvement of p63 in
cancer progression and epithelial dif-
ferentiation is very complex. The bal-
ance between TAp63 and DNp63
isoforms dictates the cell fate: survival
and transformation versus cell death.
Not only are DNp63 isoforms inhibitors
of TAp63 but also have independent
transcriptional activities controlling
epidermal development. TAp63 iso-
forms have a minor role in epidermal
differentiation, but they contribute to
maintenance of adult skin stem cells by
regulating cellular senescence and
genomic stability, and thereby they
prevent premature tissue aging. Char-
acterization of isoform-specific p63
knockout mice or mutant p63 knock-
in mice is necessary for increasing our
understanding of the roles of the vari-
ous p63 isoforms and mutants in the
biological processes in which they act.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work has been supported by a grant from the
European Union: FP6 Integrated Project Epistem
LSHB-CT-2005-019067. WD is further supported
by the Flanders Institute for Biotechnology (VIB),
Ghent University, and several grants. COST
action SKINBAD BM0903. Belgian grants: Inter-
university Attraction Poles, IAP 6/18. Flemish
grants: Fonds Wetenschappelijke Onderzoek
Vlaanderen, 3G.0218.06 and G.0226.09, and a
Methusalem grant from the Flemish Government
to Peter Vandenabeele (UGhent). Ghent Univer-
sity grants: BOF-GOA –12.0505.02.E. HvB thanks
the National Foundation for Ectodermal Dyspla-
sias for financial support. We apologize to many
colleagues whose contributions have not been
cited because of space constraints.
REFERENCES
Acampora D, Merlo GR, Paleari L et al. (1999)
Craniofacial, vestibular and bone defects in
mice lacking the distal-less-related gene
Dlx5. Development 126:3795–809
Adorno M, Cordenonsi M, Montagner M et al.
(2009) A Mutant-p53/Smad complex op-
poses p63 to empower TGFbeta-induced
metastasis. Cell 137:87–98
Amiel J, Bougeard G, Francannet C et al. (2001)
TP63 gene mutation in ADULT syndrome.
Eur J Hum Genet 9:642–5
Beaty TH, Murray JC, Marazita ML et al. (2010) A
genome-wide association study of cleft lip
with and without cleft palate identifies risk
variants near MAFB and ABCA4. Nat Genet
42:525–9
Bertola DR, Kim CA, Albano LM et al. (2004)
Molecular evidence that AEC syndrome and
Rapp-Hodgkin syndrome are variable ex-
pression of a single genetic disorder. Clin
Genet 66:79–80
Birkaya B, Ortt K, Sinha S (2007) Novel in vivo
targets of DeltaNp63 in keratinocytes identi-
fied by a modified chromatin immunopreci-
pitation approach. BMC Mol Biol 8:43
Blanpain C, Fuchs E (2009) Epidermal home-
ostasis: a balancing act of stem cells in the
skin. Nat Rev Mol Cell Biol 10:207–17
Bourdon JC (2007) p53 Family isoforms. Curr
Pharm Biotechnol 8:332–6
Candi E, Dinsdale D, Rufini A et al. (2007a)
TAp63 and DeltaNp63 in cancer and epi-
dermal development. Cell Cycle 6:274–85
Candi E, Rufini A, Terrinoni A et al. (2006a)
Differential roles of p63 isoforms in epider-
mal development: selective genetic comple-
mentation in p63 null mice. Cell Death
Differ 13:1037–47
Candi E, Rufini A, Terrinoni A et al. (2007b)
DeltaNp63 regulates thymic development
through enhanced expression of FgfR2 and
Jag2. Proc Natl Acad Sci USA
104:11999–2004
Candi E, Terrinoni A, Rufini A et al. (2006b) p63 is
upstream of IKK alpha in epidermal devel-
opment. J Cell Sci 119:4617–22
Capdevila J, Izpisua Belmonte JC (2001) Pattern-
ing mechanisms controlling vertebrate limb
development. Annu Rev Cell Dev Biol
17:87–132
Carroll DK, Carroll JS, Leong CO et al. (2006) p63
regulates an adhesion programme and cell
survival in epithelial cells. Nat Cell Biol
8:551–61
Celli J, Duijf P, Hamel BC et al. (1999) Hetero-
zygous germline mutations in the p53
homolog p63 are the cause of EEC syndrome.
Cell 99:143–53
Cheng W, Jacobs WB, Zhang JJ et al. (2006)
DeltaNp63 plays an anti-apoptotic role in
ventral bladder development. Development
133:4783–92
Chikh A, Sayan E, Thibaut S et al. (2007)
Expression of GATA-3 in epidermis and hair
follicle: relationship to p63. Biochem Bio-
phys Res Commun 361:1–6
Chitayat D, Babul R, Silver MM et al. (1996)
Terminal deletion of the long arm of
chromosome 3 [46,XX,del(3)(q27-qter)].
Am J Med Genet 61:45–8
Cho MS, Chan IL, Flores ER (2010) DeltaNp63
transcriptionally regulates brachyury, a gene
with diverse roles in limb development,
tumorigenesis and metastasis. Cell Cycle 9:
2434–41
Clements SE, Techanukul T, Holden ST et al.
(2010) Rapp-Hodgkin and Hay-Wells ecto-
dermal dysplasia syndromes represent a
variable spectrum of the same genetic
disorder. Br J Dermatol 163:624–9
Collavin L, Lunardi A, Del Sal G (2010) p53-
family proteins and their regulators: hubs
and spokes in tumor suppression. Cell Death
Differ 17:901–11
Crum CP, McKeon FD (2010) p63 in epithelial
survival, germ cell surveillance, and neopla-
sia. Annu Rev Pathol 5:349–71
de Biase D, Morandi L, Degli Esposti R et al.
(2010) p63 short isoforms are found in
invasive carcinomas only and not in benign
breast conditions. Virchows Arch 456:395–401
de Guzman Strong C, Wertz PW, Wang C et al.
(2006) Lipid defect underlies selective skin
barrier impairment of an epidermal-specific
deletion of Gata-3. J Cell Biol 175:661–70
de Mollerat XJ, Gurrieri F, Morgan CT et al. (2003)
A genomic rearrangement resulting in a
tandem duplication is associated with split
hand-split foot malformation 3 (SHFM3) at
10q24. Hum Mol Genet 12:1959–71
Del Campo M, Jones MC, Veraksa AN et al.
(1999) Monodactylous limbs and abnormal
genitalia are associated with hemizygosity
for the human 2q31 region that includes the
HOXD cluster. Am J Hum Genet 65:104–10
Deyoung MP, Ellisen LW (2007) p63 and p73 in
human cancer: defining the network. Onco-
gene 26:5169–83
Dianzani I, Garelli E, Gustavsson P et al. (2003)
Rapp-Hodgkin and AEC syndromes due to a
new frameshift mutation in the TP63 gene.
J Med Genet 40:e133
Dohn M, Zhang S, Chen X (2001) p63alpha and
DeltaNp63alpha can induce cell cycle arrest
and apoptosis and differentially regulate p53
target genes. Oncogene 20:3193–205
Duijf PH, van Bokhoven H, Brunner HG (2003)
Pathogenesis of split-hand/split-foot malfor-
mation. Hum Mol Genet 12 Spec No
1:R51–60
Duijf PH, Vanmolkot KR, Propping P et al. (2002)
Gain-of-function mutation in ADULT syn-
drome reveals the presence of a second
transactivation domain in p63. Hum Mol
Genet 11:799–804
Faiyaz-Ul-Haque M, Zaidi SH, King LM et al.
(2005) Fine mapping of the X-linked split-
hand/split-foot malformation (SHFM2) locus
to a 5.1-Mb region on Xq26.3 and analysis of
candidate genes. Clin Genet 67:93–7
Flores ER (2007) The roles of p63 in cancer. Cell
Cycle 6:300–4
Flores ER, Sengupta S, Miller JB et al. (2005)
Tumor predisposition in mice mutant for p63
and p73: evidence for broader tumor sup-
pressor functions for the p53 family. Cancer
Cell 7:363–73
Ghioni P, Bolognese F, Duijf PH et al. (2002)
Complex transcriptional effects of p63 iso-
forms: identification of novel activation and
repression domains. Mol Cell Biol
22:8659–68
Gonfloni S, Di Tella L, Caldarola S et al. (2009)
Inhibition of the c-Abl-TAp63 pathway pro-
tects mouse oocytes from chemotherapy-
induced death. Nat Med 15:1179–85
Gressner O, Schilling T, Lorenz K et al. (2005)
TAp63alpha induces apoptosis by activating
signaling via death receptors and mitochon-
dria. EMBO J 24:2458–71
www.jidonline.org 1205
H Vanbokhoven et al.
p63, a Story of Mice and Men
Gritli-Linde A (2010) p63 and IRF6: brothers in
arms against cleft palate. J Clin Invest
120:1386–9
Guo X, Keyes WM, Papazoglu C et al. (2009)
TAp63 induces senescence and suppresses
tumorigenesis in vivo. Nat Cell Biol
11:1451–7
Helton ES, Zhu J, Chen X (2006) The unique
NH2-terminally deleted (DeltaN) residues,
the PXXP motif, and the PPXY motif are
required for the transcriptional activity of
the DeltaN variant of p63. J Biol Chem
281:2533–42
Hu Y, Baud V, Delhase M et al. (1999) Abnormal
morphogenesis but intact IKK activation in
mice lacking the IKKalpha subunit of Ikap-
paB kinase. Science 284:316–20
Hu Y, Baud V, Oga T et al. (2001) IKKalpha
controls formation of the epidermis indepen-
dently of NF-kappaB. Nature 410:710–4
Ianakiev P, Kilpatrick MW, Toudjarska I et al.
(2000) Split-hand/split-foot malformation is
caused by mutations in the p63 gene on
3q27. Am J Hum Genet 67:59–66
Ihrie RA, Marques MR, Nguyen BT et al. (2005)
Perp is a p63-regulated gene essential for
epithelial integrity. Cell 120:843–56
Indelman M, Bergman R, Lurie R et al. (2002) A
missense mutation in CDH3, encoding P-
cadherin, causes hypotrichosis with juvenile
macular dystrophy. J Invest Dermatol
119:1210–3
Itin PH (2009) Rationale and background as basis
for a new classification of the ectodermal
dysplasias. Am J Med Genet A 149A:1973–6
Kannu P, Savarirayan R, Ozoemena L et al. (2006)
Rapp-Hodgkin ectodermal dysplasia syn-
drome: the clinical and molecular overlap
with Hay-Wells syndrome. Am J Med Genet
A 140:887–91
Kantaputra PN, Hamada T, Kumchai T et al.
(2003) Heterozygous mutation in the SAM
domain of p63 underlies Rapp-Hodgkin
ectodermal dysplasia. J Dent Res 82:433–7
Kaufman CK, Zhou P, Pasolli HA et al. (2003)
GATA-3: an unexpected regulator of cell
lineage determination in skin. Genes Dev
17:2108–22
Keyes WM, Vogel H, Koster MI et al. (2006) p63
heterozygous mutant mice are not prone to
spontaneous or chemically induced tumors.
Proc Natl Acad Sci USA 103:8435–40
Keyes WM, Wu Y, Vogel H et al. (2005) p63
deficiency activates a program of cellular
senescence and leads to accelerated aging.
Genes Dev 19:1986–99
Kjaer KW, Hansen L, Schwabe GC et al. (2005)
Distinct CDH3 mutations cause ectodermal
dysplasia, ectrodactyly, macular dystrophy
(EEM syndrome). J Med Genet 42:292–8
Kondo S, Schutte BC, Richardson RJ et al. (2002)
Mutations in IRF6 cause Van der Woude and
popliteal pterygium syndromes. Nat Genet
32:285–9
Koster MI, Dai D, Marinari B et al. (2007a) p63
induces key target genes required for epi-
dermal morphogenesis. Proc Natl Acad Sci
USA 104:3255–60
Koster MI, Dai D, Roop DR (2007b) Conflicting
roles for p63 in skin development and
carcinogenesis. Cell Cycle 6:269–73
Koster MI, Kim S, Mills AA et al. (2004) p63 is
the molecular switch for initiation of an
epithelial stratification program. Genes Dev
18:126–31
Koster MI, Lu SL, White LD et al. (2006)
Reactivation of developmentally expressed
p63 isoforms predisposes to tumor develop-
ment and progression. Cancer Res 66:3981–6
Koster MI, Marinari B, Payne AS et al. (2009)
DeltaNp63 knockdown mice: A mouse
model for AEC syndrome. Am J Med Genet
A 149A:1942–7
Kouwenhoven EN, van Heeringen SJ, Tena JJ et al.
(2010) Genome-wide profiling of p63 DNA-
binding sites identifies an element that
regulates gene expression during limb devel-
opment in the 7q21 SHFM1 locus. PLoS
Genet 6:e1001065
Kurata S, Okuyama T, Osada M et al. (2004) p51/
p63 Controls subunit alpha3 of the major
epidermis integrin anchoring the stem cells
to the niche. J Biol Chem 279:50069–77
Kurita T, Cunha GR, Robboy SJ et al. (2005)
Differential expression of p63 isoforms in
female reproductive organs. Mech Dev
122:1043–55
Lang GA, Iwakuma T, Suh YA et al. (2004) Gain
of function of a p53 hot spot mutation in a
mouse model of Li-Fraumeni syndrome. Cell
119:861–72
Lena AM, Shalom-Feuerstein R, di Val Cervo PR
et al. (2008) miR-203 represses ‘‘stemness’’
by repressing DeltaNp63. Cell Death Differ
15:1187–95
Leoyklang P, Siriwan P, Shotelersuk V (2006) A
mutation of the p63 gene in non-syndromic
cleft lip. J Med Genet 43:e28
Lin YL, Sengupta S, Gurdziel K et al. (2009) p63
and p73 transcriptionally regulate genes
involved in DNA repair. PLoS Genet
5:e1000680
Liu C, Nakamura E, Knezevic V et al. (2003) A
role for the mesenchymal T-box gene Bra-
chyury in AER formation during limb devel-
opment. Development 130:1327–37
Livera G, Petre-Lazar B, Guerquin MJ et al. (2008)
p63 null mutation protects mouse oocytes
from radio-induced apoptosis. Reproduction
135:3–12
Lo Iacono N, Mantero S, Chiarelli A et al. (2008)
Regulation of Dlx5 and Dlx6 gene expres-
sion by p63 is involved in EEC and SHFM
congenital limb defects. Development
135:1377–88
Mangiulli M, Valletti A, Caratozzolo MF et al.
(2009) Identification and functional charac-
terization of two new transcriptional variants
of the human p63 gene. Nucleic Acids Res
37:6092–104
Marinari B, Ballaro C, Koster MI et al. (2009)
IKKalpha is a p63 transcriptional target
involved in the pathogenesis of ectodermal
dysplasias. J Invest Dermatol 129:60–9
McGrath JA, Duijf PH, Doetsch V et al. (2001)
Hay-Wells syndrome is caused by hetero-
zygous missense mutations in the SAM
domain of p63. Hum Mol Genet 10:221–9
Medawar A, Virolle T, Rostagno P et al. (2008)
DeltaNp63 is essential for epidermal com-
mitment of embryonic stem cells. PLoS ONE
3:e3441
Mikkola ML (2007) p63 in skin appendage
development. Cell Cycle 6:285–90
Mikkola ML, Costanzo A, Thesleff I et al. (2010)
Treasure or artifact: a decade of p63 research
speaks for itself. Cell Death Differ 17:180–3;
author reply 4–6
Mills AA, Qi Y, Bradley A (2002) Conditional
inactivation of p63 by Cre-mediated exci-
sion. Genesis 32:138–41
Mills AA, Zheng B, Wang XJ et al. (1999) p63 is
a p53 homologue required for limb and
epidermal morphogenesis. Nature 398:708–13
Moretti F, Marinari B, Lo Iacono N et al. (2010) A
regulatory feedback loop involving p63 and
IRF6 links the pathogenesis of 2 genetically
different human ectodermal dysplasias. J
Clin Invest 120:1570–7
Muller PA, Caswell PT, Doyle B et al. (2009)
Mutant p53 drives invasion by promoting
integrin recycling. Cell 139:1327–41
Ortt K, Sinha S (2006) Derivation of the consensus
DNA-binding sequence for p63 reveals
unique requirements that are distinct from
p53. FEBS Lett 580:4544–50
Osada M, Park HL, Nagakawa Y et al. (2005)
Differential recognition of response elements
determines target gene specificity for p53
and p63. Mol Cell Biol 25:6077–89
Perez CA, Pietenpol JA (2007) Transcriptional
programs regulated by p63 in normal epithe-
lium and tumors. Cell Cycle 6:246–54
Pollazzon M, Grosso S, Papa FT et al. (2009) A
9.3Mb microdeletion of 3q27.3q29 asso-
ciated with psychomotor and growth delay,
tricuspid valve dysplasia and bifid thumb.
Eur J Med Genet 52:131–3
Pozzi S, Zambelli F, Merico D et al. (2009)
Transcriptional network of p63 in human
keratinocytes. PLoS ONE 4:e5008
Proksch E, Brandner JM, Jensen JM (2008) The
skin: an indispensable barrier. Exp Dermatol
17:1063–72
Rahimov F, Marazita ML, Visel A et al. (2008)
Disruption of an AP-2alpha binding site in an
IRF6 enhancer is associated with cleft lip.
Nat Genet 40:1341–7
Rinne T, Bolat E, Meijer R et al. (2009) Spectrum
of p63 mutations in a selected patient cohort
affected with ankyloblepharon-ectodermal
defects-cleft lip/palate syndrome (AEC). Am
J Med Genet A 149A:1948–51
Rinne T, Brunner HG, van Bokhoven H (2007)
p63-associated disorders. Cell Cycle 6:262–8
Rinne T, Spadoni E, Kjaer KW et al. (2006)
Delineation of the ADULT syndrome pheno-
type due to arginine 298 mutations of the
p63 gene. Eur J Hum Genet 14:904–10
Robledo RF, Rajan L, Li X et al. (2002) The Dlx5
and Dlx6 homeobox genes are essential for
craniofacial, axial, and appendicular skeletal
development. Genes Dev 16:1089–101
1206 Journal of Investigative Dermatology (2011), Volume 131
H Vanbokhoven et al.
p63, a Story of Mice and Men
Romano RA, Birkaya B, Sinha S (2007) A
functional enhancer of keratin14 is a direct
transcriptional target of deltaNp63. J Invest
Dermatol 127:1175–86
Romano RA, Ortt K, Birkaya B et al. (2009) An
active role of the DeltaN isoform of p63 in
regulating basal keratin genes K5 and K14
and directing epidermal cell fate. PLoS ONE
4:e5623
Romano RA, Smalley K, Liu S et al. (2010)
Abnormal hair follicle development and
altered cell fate of follicular keratinocytes
in transgenic mice expressing DeltaNp63al-
pha. Development 137:1431–9
Scapoli L, Palmieri A, Martinelli M et al. (2005)
Strong evidence of linkage disequilibrium
between polymorphisms at the IRF6 locus
and nonsyndromic cleft lip with or without
cleft palate, in an Italian population. Am J
Hum Genet 76:180–3
Scherer SW, Poorkaj P, Allen T et al. (1994) Fine
mapping of the autosomal dominant split
hand/split foot locus on chromosome 7,
band q21.3-q22.1. Am J Hum Genet
55:12–20
Schilling T, Kairat A, Melino G et al. (2010)
Interference with the p53 family network
contributes to the gain of oncogenic function
of mutant p53 in hepatocellular carcinoma.
Biochem Biophys Res Commun 394:817–23
Senoo M, Pinto F, Crum CP et al. (2007) p63 Is
essential for the proliferative potential of
stem cells in stratified epithelia. Cell
129:523–36
Shimomura Y, Wajid M, Shapiro L et al. (2008) P-
cadherin is a p63 target gene with a crucial
role in the developing human limb bud and
hair follicle. Development 135:743–53
Simeone A, Acampora D, Pannese M et al. (1994)
Cloning and characterization of two mem-
bers of the vertebrate Dlx gene family. Proc
Natl Acad Sci USA 91:2250–4
Stehmeier P, Muller S (2009) Regulation of p53
family members by the ubiquitin-like SUMO
system. DNA Repair (Amst) 8:491–8
Su X, Chakravarti D, Cho MS et al. (2010) TAp63
suppresses metastasis through coordinate
regulation of Dicer and miRNAs. Nature
467:986–90
Su X, Cho MS, Gi YJ et al. (2009a) Rescue of key
features of the p63-null epithelial phenotype
by inactivation of Ink4a and Arf. EMBO J
28:1904–15
Su X, Paris M, Gi YJ et al. (2009b) TAp63 prevents
premature aging by promoting adult stem
cell maintenance. Cell Stem Cell 5:64–75
Suh EK, Yang A, Kettenbach A et al. (2006) p63
protects the female germ line during meiotic
arrest. Nature 444:624–8
Testoni B, Borrelli S, Tenedini E et al. (2006)
Identification of new p63 targets in human
keratinocytes. Cell Cycle 5:2805–11
Thomason HA, Zhou H, Kouwenhoven EN et al.
(2010) Cooperation between the transcrip-
tion factors p63 and IRF6 is essential to
prevent cleft palate in mice. J Clin Invest
120:1561–9
Truong AB, Kretz M, Ridky TW et al. (2006) p63
regulates proliferation and differentiation
of developmentally mature keratinocytes.
Genes Dev 20:3185–97
Ugur SA, Tolun A (2008) Homozygous WNT10b
mutation and complex inheritance in split-
hand/foot malformation. Hum Mol Genet
17:2644–53
van Bokhoven H, Hamel BC, Bamshad M et al.
(2001) p63Gene mutations in eec syndrome,
limb-mammary syndrome, and isolated split
hand-split foot malformation suggest a geno-
type-phenotype correlation. Am J Hum
Genet 69:481–92
Vigano MA, Lamartine J, Testoni B et al. (2006)
New p63 targets in keratinocytes identified by
a genome-wide approach. EMBO J 25:5105–16
Wolff S, Talos F, Palacios G et al. (2009) The
alpha/beta carboxy-terminal domains of p63
are required for skin and limb development.
New insights from the Brdm2 mouse which
is not a complete p63 knockout but ex-
presses p63 gamma-like proteins. Cell Death
Differ 16:1108–17
Yang A, Schweitzer R, Sun D et al. (1999) p63 is
essential for regenerative proliferation in
limb, craniofacial and epithelial develop-
ment. Nature 398:714–8
Yang A, Zhu Z, Kapranov P et al. (2006)
Relationships between p63 binding, DNA
sequence, transcription activity, and biolo-
gical function in human cells. Mol Cell
24:593–602
Yi R, Poy MN, Stoffel M et al. (2008) A skin
microRNA promotes differentiation by re-
pressing ‘‘stemness’’. Nature 452:225–9
Zucchero TM, Cooper ME, Maher BS et al. (2004)
Interferon regulatory factor 6 (IRF6) gene
variants and the risk of isolated cleft lip or
palate. N Engl J Med 351:769–80
www.jidonline.org 1207
H Vanbokhoven et al.
p63, a Story of Mice and Men
